ORMP — Oramed Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $171.80m
- $121.19m
- $2.00m
Brief: Oramed Pharma Appoints Ben Shapiro To Its Board Of Directors
Brief: Oramed Pharmaceuticals Inc Increases Size Of Its Board By One
Brief: Oramed Pharmaceuticals Issues Shareholder Update
U.S. STOCKS ON THE MOVE-Boeing, Beyond Meat, Victoria's Secret
Oramed plunges as type 2 diabetes drug fails in late-stage study
U.S. STOCKS ON THE MOVE-Crypto stocks, Bed Bath & Beyond, Disney
Oramed plunges as type 2 diabetes drug fails in late-stage study
Brief: Oramed Announces Top-Line Results From Phase 3 Trial Of ORMD-0801 For The Treatment Of Type 2 Diabetes
Brief: Oramed Gets U.S. Combination Therapy Patent For Oral GLP-1 & Insulin
Brief: Oramed Pharmaceuticals Has $160 Million In Cash And Investments As Of Sept 30
Brief: Oramed Announces Positive Safety And Efficacy Data From Its Phase 2 Clinical Trial Of Ormd-0801
Brief: Oramed Signs Definitive Deal With Medicox To Commercialize Oral Insulin In South Korea
Brief: Oramed Reports Third Quarter 2022 Financial Results
Brief: Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data For Its Oral Covid-19 Vaccine
Brief: Oramed Reports Positive Top-Line Results From Phase 2 NASH Trial
Brief: Oramed Pharmaceuticals Inc - On Sept 1, 2022, Co And Its Subsidiary, Entered Into A Non-Binding Memorandum Of Agreement With Medicox Co. Ltd.
U.S. STOCKS ON THE MOVE-Walmart, Amazon.com, TransUnion
U.S. STOCKS ON THE MOVE-Paccar, natural gas firms, McDonald's, Walmart
Oramed rises as enrollment hits 50% in late-stage oral insulin trial